Eclosion2 SA, acting on behalf of the Eclosion2 & Cie SCPC fund, has notified the French Financial Markets Authority (AMF) that on August 6 it fell below the thresholds of 10% of both the share capital and voting rights in Geneuro, following the sale of shares on the market.
The declarant specified that, as of that date and as of today, it holds on behalf of the fund 2,955,516 Geneuro shares, representing an equal number of voting rights. This corresponds to 9.93% of the share capital and voting rights of the biotechnology company.
